HK1247119A1 - 一種治療方法和用於所述治療方法中的化合物 - Google Patents
一種治療方法和用於所述治療方法中的化合物Info
- Publication number
- HK1247119A1 HK1247119A1 HK18106820.3A HK18106820A HK1247119A1 HK 1247119 A1 HK1247119 A1 HK 1247119A1 HK 18106820 A HK18106820 A HK 18106820A HK 1247119 A1 HK1247119 A1 HK 1247119A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- compounds
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Urology & Nephrology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2015900336A AU2015900336A0 (en) | 2015-02-04 | A method of treatment and compounds for use therein | |
PCT/AU2016/050065 WO2016123672A1 (en) | 2015-02-04 | 2016-02-04 | A method of treatment and compounds for use therein |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1247119A1 true HK1247119A1 (zh) | 2018-09-21 |
Family
ID=56563241
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK18106820.3A HK1247119A1 (zh) | 2015-02-04 | 2018-05-25 | 一種治療方法和用於所述治療方法中的化合物 |
Country Status (6)
Country | Link |
---|---|
US (1) | US10328075B2 (zh) |
EP (1) | EP3253388A4 (zh) |
CN (1) | CN107847503A (zh) |
AU (1) | AU2016214975A1 (zh) |
HK (1) | HK1247119A1 (zh) |
WO (1) | WO2016123672A1 (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA201892008A1 (ru) | 2016-04-21 | 2019-06-28 | Астросайт Фармасьютикалс, Инк. | Соединения и способы лечения неврологических и сердечно-сосудистых состояний |
AU2017348182A1 (en) * | 2016-10-26 | 2019-05-16 | Proteostasis Therapeutics, Inc. | N-phenyl-2-(3-phenyl-6-oxo-1,6-dihydropyridazin-1-yl)acetamide derivatives for treating cystic fibrosis |
CN112218638A (zh) | 2018-02-09 | 2021-01-12 | 阿斯特罗赛特制药公司 | 用于治疗成瘾和相关病症的化合物和方法 |
WO2020069068A1 (en) | 2018-09-26 | 2020-04-02 | Astrocyte Pharmaceuticals, Inc. | Polymorphic compounds and uses thereof |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003074069A2 (en) * | 2002-03-07 | 2003-09-12 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with the n-formyl peptide receptor 1 (fpr 1) |
AU2011270872A1 (en) | 2010-06-24 | 2013-01-31 | Allergan, Inc. | Derivatives of cycloalkyl- and cycloalkenyl-1,2-dicarboxylic acid compounds having formyl peptide receptor like-1 (FPRL-1) agonist or antagonist activity |
CA2819457A1 (en) * | 2010-12-03 | 2012-06-07 | Allergan, Inc. | Pharmaceutical compositions comprising 3,4-dihydroisoquinolin-2(1h)-yl-3-phenylurea derivatives having formyl peptide receptor like-1 (fprl-1) agonist or antagonist activity |
US8729096B2 (en) * | 2012-02-16 | 2014-05-20 | Allergan, Inc. | Imidazolidine-2,4-dione derivatives as N-formyl peptide receptor 2 modulators |
-
2016
- 2016-02-04 CN CN201680020925.XA patent/CN107847503A/zh active Pending
- 2016-02-04 AU AU2016214975A patent/AU2016214975A1/en not_active Abandoned
- 2016-02-04 US US15/548,555 patent/US10328075B2/en not_active Expired - Fee Related
- 2016-02-04 EP EP16746007.0A patent/EP3253388A4/en not_active Withdrawn
- 2016-02-04 WO PCT/AU2016/050065 patent/WO2016123672A1/en active Application Filing
-
2018
- 2018-05-25 HK HK18106820.3A patent/HK1247119A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
EP3253388A1 (en) | 2017-12-13 |
WO2016123672A1 (en) | 2016-08-11 |
EP3253388A4 (en) | 2018-11-21 |
US10328075B2 (en) | 2019-06-25 |
US20180092917A1 (en) | 2018-04-05 |
AU2016214975A1 (en) | 2017-08-10 |
CN107847503A (zh) | 2018-03-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1251614A1 (zh) | 用於惡性腫瘤的治療的方法 | |
HK1252568A1 (zh) | 一種治療方法 | |
GB201514756D0 (en) | Compound and method of use | |
HK1248552A1 (zh) | 使用川地匹坦的治療方法 | |
GB201514760D0 (en) | Compounds and method of use | |
PL3297975T3 (pl) | Sposób kompleksowej utylizacji fosfogipsów | |
GB201609786D0 (en) | Compounds and method of use | |
GB201410116D0 (en) | Method of treatment | |
HK1252692A1 (zh) | 治療或者預防蛋白質構象病的方法 | |
EP3684342C0 (en) | TREATMENT PROCEDURES | |
HK1247818A1 (zh) | 治療疾病的方法 | |
SG10201912688YA (en) | A method of treatment | |
GB201706406D0 (en) | Method of treatment | |
IL253028A0 (en) | treatment method | |
HK1247119A1 (zh) | 一種治療方法和用於所述治療方法中的化合物 | |
GB201815588D0 (en) | Method of treatment | |
GB201521886D0 (en) | A method of treating a well | |
GB201602802D0 (en) | Method of treatment | |
HK1250243A1 (zh) | 治療方法 | |
IL248847A0 (en) | Dosertalin dosage and method for treating adhd | |
GB201806609D0 (en) | A method of treatment and prognosis | |
GB201512139D0 (en) | Methods of treatment | |
GB201720439D0 (en) | Method of treatment | |
GB201718589D0 (en) | Method of treatment | |
AU2015900336A0 (en) | A method of treatment and compounds for use therein |